These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 15599385)

  • 1. Management of metastatic breast cancer: are we prepared to cope with our own success?
    Jimeno A; Cortés-Funes H; Colomer R
    Br J Cancer; 2004 Dec; 91(12):2101; author reply 2102. PubMed ID: 15599385
    [No Abstract]   [Full Text] [Related]  

  • 2. Health care costs for treatment of disseminated breast cancer.
    Dahlberg L; Lundkvist J; Lindman H
    Eur J Cancer; 2009 Jul; 45(11):1987-91. PubMed ID: 19398326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impact of the chemotherapy protocols for metastatic breast cancer on the treatment cost and the survival time of 371 patients treated in three hospitals of the Rhone-Alpes region].
    Paviot BT; Bachelot T; Clavreul G; Jacquin JP; Mille D; Rodrigues JM
    Bull Cancer; 2009 Oct; 96(10):929-40. PubMed ID: 19696006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness, chemotherapy, and the clinician.
    Griggs JJ; Sorbero ME
    Breast Cancer Res Treat; 2009 Apr; 114(3):597-8. PubMed ID: 18695985
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.
    Hassett MJ; O'Malley AJ; Pakes JR; Newhouse JP; Earle CC
    J Natl Cancer Inst; 2006 Aug; 98(16):1108-17. PubMed ID: 16912263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
    Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib: new drug. For some women with metastatic breast cancer.
    Prescrire Int; 2009 Feb; 18(99):9. PubMed ID: 19382400
    [No Abstract]   [Full Text] [Related]  

  • 9. New advances in the management of metastatic breast cancer.
    Glück S
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S12-6. PubMed ID: 16280104
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cancer chemotherapy in DPC].
    Kubota T
    Gan To Kagaku Ryoho; 2004 Aug; 31(8):1174-8. PubMed ID: 15332539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Has first-line therapy had an impact on general outcome in metastatic breast cancer?
    McArthur HL; Hudis CA
    Future Oncol; 2007 Aug; 3(4):411-8. PubMed ID: 17661716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of intensive adjuvant chemotherapy for high-risk breast cancer: is tailored and dose-escalated chemotherapy with growth factor support (GFS) more costly and less effective than marrow-supported high-dose chemotherapy - results from a randomized study.
    Kellokumpu-Lehtinen P; Bergh J; Salminen E; Wiklund T; Lehtinen S; Aronen P; Sintonen H
    Acta Oncol; 2007; 46(2):146-52. PubMed ID: 17453362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic/societal burden of metastatic breast cancer: a US perspective.
    Allen JM
    Am J Manag Care; 2010 Sep; 16(9):697-704. PubMed ID: 20873957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlling the cost of breast cancer.
    Gill D; Bruce D; Tan PH
    Eur J Cancer Care (Engl); 2011 Nov; 20(6):703-7. PubMed ID: 21883568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of dose-dense chemotherapy in the management of breast cancer.
    Norton L
    Clin Adv Hematol Oncol; 2006 Jan; 4(1):36-7. PubMed ID: 16562368
    [No Abstract]   [Full Text] [Related]  

  • 16. Ixabepilone in metastatic breast cancer: complement or alternative to taxanes?
    Tan AR; Toppmeyer DL
    Clin Cancer Res; 2008 Nov; 14(21):6725-9. PubMed ID: 18980963
    [No Abstract]   [Full Text] [Related]  

  • 17. Breast cancer breakthrough in gene profilings?
    Bateman C
    S Afr Med J; 2009 Nov; 99(11):780-2. PubMed ID: 20218471
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy.
    Andreopoulou E; Hortobagyi GN
    J Clin Oncol; 2008 Aug; 26(22):3660-2. PubMed ID: 18669447
    [No Abstract]   [Full Text] [Related]  

  • 19. Does reimbursement influence chemotherapy treatment for cancer patients?
    Jacobson M; O'Malley AJ; Earle CC; Pakes J; Gaccione P; Newhouse JP
    Health Aff (Millwood); 2006; 25(2):437-43. PubMed ID: 16522584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant anthracyclines and taxanes: quantifying the costs of therapeutic advances in breast cancer.
    Morris PG; Bach PB
    Onkologie; 2009 Sep; 32(8-9):464-6. PubMed ID: 19745589
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.